Influence of Cigarette Smoking Habit on Clozapine-to-Norclozapine Ratio in Male Patients.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY

Journal of Research in Pharmacy Practice Pub Date : 2023-11-27 eCollection Date: 2023-01-01 DOI:10.4103/jrpp.jrpp_37_23

Roberto Lozano, Carina Bona

{"title":"Influence of Cigarette Smoking Habit on Clozapine-to-Norclozapine Ratio in Male Patients.","authors":"Roberto Lozano, Carina Bona","doi":"10.4103/jrpp.jrpp_37_23","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to evaluate the influence of cigarette smoking habit on the clozapine (CLZ)-to-norclozapine (norCLZ) ratio in male patients.Methods: The sample consisted of plasma concentration of CLZ and norCLZ data set. The mean values of CLZ, norCLZ, and CLZ-to-norCLZ, between male patients who smoke versus nonsmokers were compared.Findings: CLZ mean plasma level of 142 ± 80 ng/ml and 305 ± 159 ng/ml, norCLZ mean plasma level of 93 ± 72 ng/ml and 234 ± 62 ng/ml, and mean CLZ-to-norCLZ plasma level ratio of 2.1 ± 1.1 and 1.5 ± 0.5, were obtained respectively for male patients who smoke and nonsmokers.Conclusion: This study has shown a significant decrease in CLZ and norCLZ plasma levels, and an increase in the CLZ-to-norCLZ ratio, in smokers as compared to nonsmokers, due to an increase in the clearance of CLZ and norCLZ by smoking induction of CYP 1A2 and glucuronidation by uridyl glucuronyl transferase enzymes (UGT), mainly UGT 1A4, respectively, as the most probable cause.","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 1","pages":"29-31"},"PeriodicalIF":0.8000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10779687/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_37_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to evaluate the influence of cigarette smoking habit on the clozapine (CLZ)-to-norclozapine (norCLZ) ratio in male patients.

Methods: The sample consisted of plasma concentration of CLZ and norCLZ data set. The mean values of CLZ, norCLZ, and CLZ-to-norCLZ, between male patients who smoke versus nonsmokers were compared.

Findings: CLZ mean plasma level of 142 ± 80 ng/ml and 305 ± 159 ng/ml, norCLZ mean plasma level of 93 ± 72 ng/ml and 234 ± 62 ng/ml, and mean CLZ-to-norCLZ plasma level ratio of 2.1 ± 1.1 and 1.5 ± 0.5, were obtained respectively for male patients who smoke and nonsmokers.

Conclusion: This study has shown a significant decrease in CLZ and norCLZ plasma levels, and an increase in the CLZ-to-norCLZ ratio, in smokers as compared to nonsmokers, due to an increase in the clearance of CLZ and norCLZ by smoking induction of CYP 1A2 and glucuronidation by uridyl glucuronyl transferase enzymes (UGT), mainly UGT 1A4, respectively, as the most probable cause.

查看原文本刊更多论文

吸烟习惯对男性患者氯氮平与诺氯氮平比例的影响

研究目的本研究旨在评估吸烟习惯对男性患者氯氮平（CLZ）-去氯氮平（norCLZ）比值的影响：样本包括CLZ和norCLZ的血浆浓度数据集。比较了吸烟与不吸烟男性患者的 CLZ、norCLZ 和 CLZ 与 norCLZ 的平均值：结果：吸烟和不吸烟男性患者的 CLZ 平均血浆水平分别为 142 ± 80 ng/ml 和 305 ± 159 ng/ml，norCLZ 平均血浆水平分别为 93 ± 72 ng/ml 和 234 ± 62 ng/ml，CLZ 与 norCLZ 平均血浆水平比分别为 2.1 ± 1.1 和 1.5 ± 0.5：本研究表明，与不吸烟者相比，吸烟者的CLZ和norCLZ血浆水平明显下降，CLZ与norCLZ的比值上升，这可能是由于吸烟分别诱导CYP 1A2和尿苷葡萄糖醛酸转移酶（UGT）（主要是UGT 1A4）的葡萄糖醛酸化作用，从而增加了CLZ和norCLZ的清除率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

21 weeks

期刊介绍： The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.